Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
First Claim
Patent Images
1. A method of treating a human eye for recurrent corneal erosion comprising:
- topically administering to the human eye an ophthalmic solution for treating recurrent corneal erosion, the solution consisting of;
between about 5% and 25% by weight of a polymer of glucose having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole;
one or more inorganic salts including between about 0.5% and 2% by weight NaCl;
between about 0.5% and 2% by weight hyaluronic acid;
at least about 71% by weight water; and
less than about 360 ppm carbon dioxide;
wherein the ophthalmic solution has a pH between about 6.5 and 7.5 and has an osmolality of between about 320-350 mOsmol/kg solution;
wherein the human eye to which the ophthalmic solution is administered suffers from recurrent corneal erosion; and
wherein the ophthalmic solution is administered to the eye about every 3 to 8 hours for about 2 to 16 weeks.
0 Assignments
0 Petitions
Accused Products
Abstract
An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
16 Citations
13 Claims
-
1. A method of treating a human eye for recurrent corneal erosion comprising:
-
topically administering to the human eye an ophthalmic solution for treating recurrent corneal erosion, the solution consisting of;
between about 5% and 25% by weight of a polymer of glucose having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole;
one or more inorganic salts including between about 0.5% and 2% by weight NaCl;
between about 0.5% and 2% by weight hyaluronic acid;
at least about 71% by weight water; and
less than about 360 ppm carbon dioxide;wherein the ophthalmic solution has a pH between about 6.5 and 7.5 and has an osmolality of between about 320-350 mOsmol/kg solution; wherein the human eye to which the ophthalmic solution is administered suffers from recurrent corneal erosion; and wherein the ophthalmic solution is administered to the eye about every 3 to 8 hours for about 2 to 16 weeks. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
Specification